Neurology
New treatment option for ruptured brain aneurysms
|
|
Researchers in Finland have identified an effective new treatment option for patients who have suffered a ruptured brain aneurysm, a potentially life-threatening event. Results of the new study on stent-assisted coil embolization were published today in the online edition of Radiology.
An aneurysm is a bulge or sac that develops in a weak area of a cerebral artery wall. Subarachnoid hemorrhage occurs when an aneurysm ruptures, diverting oxygen-rich blood from vital areas to the space between the brain and the skull. The ruptured vessel can be repaired surgically or through a minimally invasive procedure called embolization, in which the sac is filled with metal coils in order to prevent repeat bleeding from the aneurysm and to restore normal blood flow in the artery.
“The treatment decision is complicated in cases of acutely ruptured aneurysms,” said the study’s lead author, Olli Tähtinen, M.D., assistant professor of radiology at Tampere University Hospital in Tampere, Finland.
Strong link found between concussions and brain tissue injury
|
|
Concussions, whether from an accident, sporting event, or combat, can lead to permanent loss of higher level mental processes. Scientists have debated for centuries whether concussions involve structural damage to brain tissue or whether physiological changes that merely impair the way brain cells function, explain this loss. Now, for the first time, researchers at Albert Einstein College of Medicine of Yeshiva University have linked areas of brain injury to specific altered mental processes caused by concussions.
The research, described in the August 26 edition of Radiology, provides compelling evidence that concussions involve brain damage. The findings suggest that diffusion tensor imaging (DTI), the brain scanning method used by the Einstein scientists, could help in diagnosing concussions and in assessing the effectiveness of treatments.
“DTI has been used to look at other brain disorders, but this is the first study to focus on concussions,” said Michael Lipton, M.D., Ph.D., associate director of the Gruss Magnetic Resonance Research Center (MRRC) and associate professor of radiology, of psychiatry and behavioral sciences, and of neuroscience at Einstein and lead author of the study. “It proved to be a powerful tool for detecting the subtle brain damage that we found to be associated with concussions.”
Agent Orange linked to heart disease, Parkinson’s
|
|
Agent Orange, used by U.S. forces to strip Vietnamese and Cambodian jungles during the Vietnam War, may raise the risk of heart disease and Parkinson’s disease, U.S. health advisers said on Friday.
But the evidence is only limited and far from definitive, the Institute of Medicine panel said.
“The report strongly recommends that studies examining the relationship between Parkinson’s incidence and exposures in the veteran population be performed,” the institute, an independent academy that guides federal policy, said in a statement.
Researchers Discover Possible Therapeutic Target to Slow Parkinson’s Disease
|
|
University of Medicine and Dentistry of New Jersey (UMDNJ) researchers have discovered a therapeutic target that, when manipulated, may slow the progression of or halt Parkinson’s disease, a debilitating neurodegenerative disorder that affects an estimated one million people in the U.S.
A team from the Center for Neurodegenerative and Neuroimmunologic Diseases in the Department of Neurology at the UMDNJ-Robert Wood Johnson Medical School carried out the study. M. Maral Mouradian, M.D., center director and William Dow Lovett Professor of Neurology, was its lead investigator. A paper on their findings, titled “Repression of a-synuclein expression and toxicity by microRNA-7,” appears in the July 20 edition of the Proceedings of the National Academy of Sciences (PNAS).
In this publication, the investigators report that the small RNA molecule microRNA-7, which is present in neurons, directly represses the expression of a-synuclein, a protein that, in excess, proves deleterious to certain types of brain cells.
Study singles out pesticide in Parkinson’s risk
|
|
New research provides more evidence for a link between pesticide exposure and Parkinson’s disease and pinpoints a specific risky chemical.
Dr. Jason R. Richardson of the Robert Wood Johnson Medical School in Piscataway, New Jersey, and his colleagues found that Parkinson’s disease patients were more likely to have detectable levels of beta-hexachlorocyclohexane (beta-HCH) in their blood, and also had higher average levels, than healthy individuals or Alzheimer’s disease patients.
The first evidence suggesting an association between pesticides and the degenerative brain disease Parkinson’s came out in the 1990s, but the current findings are the first to finger a specific chemical, Richardson told Reuters Health.
Most take news of genetic Alzheimer’s risk well
|
|
Adult children who have a parent with Alzheimer’s disease may want to know if they carry a gene that raises their risk of getting the mind-robbing disease. But can they handle the test result, psychologically? Findings from a study released today hint that most can handle the information.
The e4 version of the apolipoprotein E (APOE) gene is associated with an increased risk of Alzheimer’s disease, as well as impaired memory in people without dementia and with progression to Alzheimer’s disease in people with mild thinking impairment.
In the REVEAL study, researchers found that disclosing APOE test results to adult children of patients with Alzheimer’s disease “did not result in significant short-term psychological risks.”
Study Continues to Refine Most Effective Methods to Predict Alzheimer’s Disease
|
|
A new Mayo Clinic study found that the clinical criteria for mild cognitive impairment is better at predicting who will develop Alzheimer’s disease than a single memory test. This is one more piece of information to aid in the identification and early treatment of individuals most likely to develop Alzheimer’s disease. This study will be presented at the Alzheimer’s Association International Conference on Alzheimer’s Disease on July 14 in Vienna.
Alzheimer’s disease is a degenerative disorder of the brain in which nerve cells die over time, resulting in a steady loss of memory and other thinking abilities. An estimated 5.3 million Americans are living with Alzheimer’s disease, and it is the sixth-leading cause of death in the U.S. Mild cognitive impairment is a transitional state between normal aging and the earliest features of Alzheimer’s disease.
“The goal of this research is to try to predict who is going to develop Alzheimer’s disease in the future,” says Ronald Petersen, M.D., Ph.D., a neurologist at Mayo Clinic and the lead author of this study. “Ideally, we’d like to identify individuals before any damage is done in the brain. The sooner we intervene on this process with medications or other therapies, the greater impact we can have on lessening the number of people who will ultimately develop Alzheimer’s disease.”
Scientist First to Characterize Novel Syndrome of Allergy, Apraxia, Malabsorption
|
|
A landmark study conducted by Children’s Hospital & Research Center Oakland is the first to reveal a new syndrome in children that presents with a combination of allergy, apraxia and malabsorption. Autism spectrum disorders were variably present. Verbal apraxia has until now been understood to be a neurologically based speech disorder, although hints of other neurological soft signs have been described. The new study, led by Children’s Hospital & Research Center Oakland scientist and pediatric emergency medicine physician, Claudia Morris, MD, and Marilyn C. Agin, MD, a neurodevelopmental pediatrician at Saint Vincent Medical Center in New York, however, suggests that the symptoms of verbal apraxia are, at least for a sub-group of children, part of a larger, multifactorial, neurologic syndrome involving food allergies/gluten-sensitivity and nutritional malabsorption.
“While it is critical to treat verbal apraxia symptoms that often include severe delays in expressive speech production with speech therapy, we need to start asking why these kids are having these problems in the first place so that we can identify mechanisms we can actually target to treat the cause of the symptoms,” says Dr. Morris.
Published in the July/August issue of Alternative Therapies in Health and Medicine, the new study takes a major step toward identifying the potential mechanisms that may contribute to apraxia symptoms. In the study, Dr. Morris collected information from nearly 200 families with children who suffered from verbal apraxia in order to better characterize the symptoms and metabolic anomalies of a subset of children.
New tests may help spot early-stage Alzheimer’s
|
|
New tests assessing brain changes and body chemistry are showing promise at diagnosing Alzheimer’s disease in its earliest stages, aiding the search for new drugs, researchers said on Tuesday.
In one study, Irish researchers found scans measuring brain volume and a combination of memory tests accurately identified nearly 95 percent of people who had progressed from mild cognitive impairment to early Alzheimer’s disease.
In another study, U.S. researchers found that a type of brain scan that measures glucose combined with low scores on memory tests was a strong predictor of disease progression.
Clinical Trial Shows Tongue Drive System Assists Disabled
|
|
An assistive technology that enables individuals to maneuver a powered wheelchair or control a mouse cursor using simple tongue movements can be operated by individuals with high-level spinal cord injuries, according to the results of a recently completed clinical trial.
“This clinical trial has validated that the Tongue Drive system is intuitive and quite simple for individuals with high-level spinal cord injuries to use,” said Maysam Ghovanloo, an assistant professor in the School of Electrical and Computer Engineering at the Georgia Institute of Technology. “Trial participants were able to easily remember and correctly issue tongue commands to play computer games and drive a powered wheelchair around an obstacle course with very little prior training.”
At the annual conference of the Rehabilitation Engineering and Assistive Technology Society of North America (RESNA) on June 26, the researchers reported the results of the first five clinical trial subjects to use the Tongue Drive system. The trial was conducted at the Shepherd Center, an Atlanta-based catastrophic care hospital, and funded by the National Science Foundation and the Christopher and Dana Reeve Foundation.
Device shows promise for type of cerebral palsy
|
|
Treatment in the brain with a mild electrical current appears to help patients with a difficult-to-treat form of cerebral palsy, French researchers said on Wednesday.
Patients in the study were implanted with pacemaker-like devices, known as deep-brain stimulators, made by Medtronic Inc, which helped fund the study.
A team lead by Marie Vidailhet of Salpetriere University Hospital in Paris implanted the devices in 13 people who had cerebral palsy with dystonia-choreoathetosis, a common and progressively disabling movement disorder.
Measuring intellectual disability
|
|
Researchers from the University of California, Davis have developed a specific and quantitative means of measuring levels of the fragile X mental retardation 1 (FMR1) protein (FMRP), which is mutated in fragile X syndrome. The related report by Iwahashi et al, “A quantitative ELISA assay for the fragile X mental retardation 1 protein,” appears in the July 2009 issue of the Journal of Molecular Diagnostics.
Fragile X syndrome is the most common form of inherited intellectual impairment. Nearly one third of patients diagnosed with fragile X syndrome also have some degree of autism, and the mutation underlying fragile X syndrome is the most commonly known single gene cause of autism.
Fragile X syndrome is caused by low levels of the FMRP protein, which is thought to play a role in communication between nerve cells. In patients with fragile X syndrome, a sequence in the FMR1 gene that is repeated 10-40 times in normal individuals may be repeated from 200 to more than 1,000 times, decreasing levels of the FMRP protein.
Gene predicts how brain responds to fatigue, human study shows
|
|
New imaging research in the June 24 issue of The Journal of Neuroscience helps explain why sleep deprivation affects some people more than others. After staying awake all night, those who are genetically vulnerable to sleep loss showed reduced brain activity, while those who are genetically resilient showed expanded brain activity, the study found. The findings help explain individual differences in the ability to compensate for lack of sleep.
“The extent to which individuals are affected by sleep deprivation varies, with some crashing out and others holding up well after a night without sleep,” said Michael Chee, MBBS, at the Duke–National University of Singapore Graduate Medical School, an expert on sleep deprivation who was not affiliated with the study. However, studying how the brain produces these behavioral differences is difficult: researchers usually do not know whether their study participants will be vulnerable to sleep deprivation until after a study is complete. Previous studies have shown conflicting results, perhaps because the study subjects differed widely in vulnerability to sleep deprivation.
In the current study, the researchers, led by Pierre Maquet, MD, at the University of Lìege in Belgium and Derk-Jan Dijk, PhD, at the University of Surrey in the United Kingdom, avoided this problem by selecting study participants based on their genes. Previous research showed that the PERIOD3 (PER3) gene predicts how people will respond to sleep deprivation. People carry either long or short variants of the gene. Those with the short PER3 variant are resilient to sleep loss — they perform well on cognitive tasks after sleep deprivation. However, those with the long PER3 variant are vulnerable — they show deficits in cognitive performance after sleep deprivation. Now the new study explains why.
School of Dentistry Studies Link Between Oral Health and Memory
|
|
Keeping your teeth brushed and flossed can cut down on gum disease, drastically reducing risk of heart attack and stroke, dentists have warned for years. Now researchers at West Virginia University have found a clean mouth may also help preserve memory.
The National Institutes of Health (NIH) has awarded a $1.3 million grant over four years to further build on studies linking gum disease and mild to moderate memory loss.
“Older people might want to know there’s more reason to keep their mouths clean – to brush and floss – than ever,” said Richard Crout, D.M.D., Ph.D., an expert on gum disease and associate dean for research in the WVU School of Dentistry. “You’ll not only be more likely to keep your teeth, but you’ll also reduce your risk of heart attack, stroke and memory loss.”
Cupping Therapy Alleviates Carpal Tunnel Syndrome Pain
|
|
A German study published in The Journal of Pain showed that an external suction technique mainly used outside the U.S., called cupping, is effective for providing temporary relief of pain from carpal tunnel syndrome (CPS).
Researchers from Immanuel Hospital Berlin randomly divided fifty-two CPS patients into treatment and control groups. The treatment group was given wet cupping therapy in which cupping glasses are applied to skin overlaying the trapezius muscle following 5 to 10 skin punctures with a sterile lancet. A partial vacuum is created by electromechanical or manual suction within the cupping glass after it is applied to the skin.
The technique is used as a healing method in China, India, Arabia, Central Europe and parts of Africa. Cupping is applied to defined zones of the shoulder triangle which are connective tissue zones at the shoulder-neck region. The technique is believed to increase microcirculation to help relieve CPS symptoms.
